Literature DB >> 30562063

Expression and Clinical Significance of CMTM6 in Hepatocellular Carcinoma.

Xiaonian Zhu1, Guangzi Qi2, Cong Li1, Chunhua Bei1, Chao Tan1, Ying Zhang1, Wenxiang Shi1, Wen Zeng1, Juan Kong1, Yuanyuan Fu1, Shengkui Tan1.   

Abstract

This study aimed to examine the expression level and clinical significance of chemokine-like factor-like MARVEL transmembrane domain-containing family member 6 (CMTM6) in paired hepatocellular carcinoma (HCC) and adjacent nontumor tissues. The expression of CMTM6 was detected in 75 paired HCC and adjacent nontumor tissues by immunohistochemistry. Chi-square test was used to compare the difference of CMTM6 expression between HCC tissues and adjacent nontumor tissues. The clinic-pathological features and prognosis of HCC patients were collected to analyze the relationship with CMTM6 expression. The positive expression of CMTM6 in HCC tissues was significantly lower than that of adjacent nontumor tissues. The difference of CMTM6 expression between HCC tissues and paired adjacent nontumor tissues was statistically significant (p < 0.05). Furthermore, CMTM6 expression was correlated with HCC metastasis and alpha-fetoprotein (AFP) (p < 0.05). Multivariate logistic regression analysis showed tumor staging, metastasis, and AFP had a significant relationship with CMTM6 expression. In addition, the survival time of HCC patients was different between CMTM6 positive group and CMTM6 negative group by Kaplan-Meier survival analysis (p < 0.05). Downregulation of CMTM6 is related to HCC metastasis and the prognosis of HCC patients.

Entities:  

Keywords:  CMTM6; HCC; metastasis; prognosis

Mesh:

Substances:

Year:  2018        PMID: 30562063     DOI: 10.1089/dna.2018.4513

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  22 in total

1.  Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.

Authors:  Young Wha Koh; Jae-Ho Han; Seokjin Haam; Joonho Jung; Hyun Woo Lee
Journal:  Oncoimmunology       Date:  2019-06-14       Impact factor: 8.110

2.  A prognostic risk model for ovarian cancer based on gene expression profiles from gene expression omnibus database.

Authors:  Wei Fan; Xiaoyun Chen; Ruiping Li; Rongfang Zheng; Yunyun Wang; Yuzhen Guo
Journal:  Biochem Genet       Date:  2022-06-27       Impact factor: 1.890

Review 3.  CMTM6, a potential immunotherapy target.

Authors:  Jie Liang; Shaohua Li; Wei Li; Wei Rao; Shuo Xu; Haining Meng; Fengqi Zhu; Dongchang Zhai; Mengli Cui; Dan Xu; Jinzhen Cai; Bei Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-16       Impact factor: 4.553

4.  Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer.

Authors:  Shuai Shi; Hong-Yan Ma; Yin-Zhou Sang; Ying-Bo Ju; Xiao-Yun Liu; Zhi-Gang Zhang
Journal:  Biomed Res Int       Date:  2022-07-07       Impact factor: 3.246

5.  CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients.

Authors:  Xin Li; Ling Chen; Chuan Gu; Qiaoli Sun; Jia Li
Journal:  PeerJ       Date:  2020-08-17       Impact factor: 2.984

6.  OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.

Authors:  Xin Pang; Sha-Sha Wang; Mei Zhang; Jian Jiang; Hua-Yang Fan; Jia-Shun Wu; Hao-Fan Wang; Xin-Hua Liang; Ya-Ling Tang
Journal:  Cancer Immunol Immunother       Date:  2020-10-26       Impact factor: 6.968

Review 7.  The clinical and prognostic significance of CMTM6/PD-L1 in oncology.

Authors:  Mahmoud Mohammad Yaseen; Nizar Mohammad Abuharfeil; Homa Darmani
Journal:  Clin Transl Oncol       Date:  2022-03-12       Impact factor: 3.340

8.  Down-Regulated CMTM2 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.

Authors:  Shidong Zhang; Run Tian; Chunhua Bei; Huixia Zhang; Juan Kong; Chuanjun Zheng; Xin Song; Di Li; Hongzhuan Tan; Xiaonian Zhu; Shengkui Tan
Journal:  Onco Targets Ther       Date:  2020-06-17       Impact factor: 4.147

Review 9.  Chemokine-Like Factor-Like MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma: Latest Advances.

Authors:  Mengxia Li; Fangzhou Luo; Xinyao Tian; Shengyong Yin; Lin Zhou; Shusen Zheng
Journal:  Front Oncol       Date:  2020-11-13       Impact factor: 6.244

Review 10.  Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer.

Authors:  Keheng Wu; Xiaoman Li; Huadi Gu; Qiao Yang; Yingying Liu; Liang Wang
Journal:  Int J Biol Sci       Date:  2019-09-07       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.